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INTEGRATED STUDY PLAN FOR SPACE BIOPROCESSING
1.0 Approach
The objective of this study is to apply current economic evaluation
and analytical techniques to decision problems faced by the space bioprocessing
program. Specifically, this study will enable NASA decision makers to choose
the candidate substances, after ranking them according to their potential
economic benefit. Later phases will focus on program analysis, where the
relative risks and benefits will be analyzed in a decision tree analysis in
order to allow NASA to determine the proper mix of projects to undertake in
the STS program--projects with high risk and low risk, as well as high poten-
tial payoff and low potential payoff.
Our approach to the planning of this project is based upon two years of
specific experience in the analysis of the economics of space materials
processing and consists of work to be completed in three separate phases.
Phase I will be completed under this contract and is aimed at determin-
ing the appropriate evaluation technique necessary to obtain measures of the
potential economic benefits which may occur as the result of the pursuit of
various space bioprocessing endeavors. During this phase, ECON will also
review the treatment of each disease which would be impacted by a successful
outcome of space bioprocessing and specify data and other input needs for
each candidate substance. Phases II and III, to be performed in subsequent
years, will consist of actual data collection for benefit evaluation, and
program analysis and evaluation, respectively. Each phase is described in
more detail below.
2.0 Study Data Base
The variables of the data base will be specified during the current
phase, while actual data collection will take place during the following
year, in Phase II. The input factors will be determined from the evaluation
technique which is selected and the specific diseases and treatments involved.
Our previous experience with the benefit analysis of space bioprocessing
indicates that the data base is likely to include the following factors:
•	 Number of persons annually afflicted with diseases for which space
processing can have an impact
•	 Number of persons entering each treatment state or change in num-
ber of persons that will enter the treatment state
•	 Costs associated with each treatment or recovery state
•	 Earnings per person for each disease and treatment state
•	 Probabilities of a person entering various treatment, recovery or
death states (usually from epidemiology statistics)
•	 Potential efficacy of new pharmaceutical products or treatment
techniques based on assumed successful outcome of space processing
of candidate pharmaceutical substances
•	 Costs of comparative production techniques.
It is important to realize that the development of the data base, like
the evolution to the study, is a step-by-step process with each succeeding
procedure resulting from and being consistent with the results of the pre-
vious work. This approach is key to maintaining the flexibility necessary to
assure that a study of this scope can be modified to fit NASA's needs pre-
cisely as they develop over the study period. A description of the specific
tasks of each phase follows.
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t2.1 Phase I --General Methodology and Data Specification
The purpose of Phase I is to determine the appropriate evaluation
technique necessary to obtain measures of the potential economic benefits
which may occur as the result of the successful pursuit of various space
bioprocessing endeavors. In addition to selecting the appropriate evaluation
technique, ECON will specify the specific data and other input needs for each
of the space processing candidate substances after a systematic review of
the treatment of each disease that would be impacted by a successful outcome
of space processing of biological materials. The specific tasks in Phase I
are:
2.1.1. In Task 1 ECON will evaluate currently utilized techniques for
health program benefit evaluation, including the Markov process technique
utilized by ECON for a NASA Headquarters project on the economics of space
processing.	 ECON will perform a literature review, including a survey of
government documents on the subject of health treatment systems economic
benefit evaluation techniques. Concurrent with the review of benefit evalua-
tion methodologies, ECON will classify the candidate substances or processes
according to how economic benefits would be derived. For example, benefit
classification categories such as reduced mortality, increased longevity,
reduced treatment costs, expansion of treatment population and reduced pro-
duction costs might be employed. While reviewing candidate techniques, ECON
will evaluate whether the economic techniques are applicable to the evalua-
tion of disease treatment benefits related to the list of benefit classifi-
cation categories of the candidates. The following examples are typical of
candidate substances:
Preliminary Benefit Analysis of Biological Space Processing, ECON, Inc.,
September 1, 1976, Contract NASW-2558, ECON, Report No. 76-119-1.
I•	 Erythropoietin
•	 Lymphocyte Subgroup Fractions
•	 Human Growth Hormones
•	 Urokinase
•	 Human Insulin
•	 Vaccines.
Based on current knowledge, it is estimated that this list could be expanded
to some 30 to 50 candidates during Phase I of this study.
The criteria to be utilized in choosing the appropriate evaluation tech-
nique are: (1) it is generally accepted by the health treatment community;
(2) it is easily understandable and can be transferred to NASA for internal
use if desired; (3) it offers the appropriate degree of accuracy and sophis-
tication without being overly complex; and (4) the results are capable of
being compared with each other and with the results of other studies.
ECON will then select one or more techniques to be utilized in this
study.
2.1.2 In the second task of Phase I, ECON will analyze each of the
the disease treatments corresponding to the candidates for space bioprocessing
and determine precisely what data are needed and in what form the data should
be before an evaluation of the economic benefits related to that disease
treatment. Several man-days will be spent on each candidate product to
determine what disease or diseases the new product would treat, what the
present treatment modes are and what the potential new treatment techniques
would be.
For the 30 to 50 candidate substances, ECON will determine the
information needed for the economic evaluation of each candidate. NASA
will supply ECON with sufficient information about each candidate biological
substance or process to allow ECON to chart out what further data on costs,
statistics incidence of disease, treatment state, transition probabilities and
production costs are needed for benefit evaluation. This breakdown will
direct the detailed data gathering efforts of Phase II, and this information
will then be used to perform the economic evaluation. Although several tech-
niques might be chosen to evaluate the potential beneficial outcome of the
candidate substances, the important criterion is whether the outputs of the
evaluation techniques can be compared to each other.
ECON will produce a written description telling the user of the evalu-
ation technique how to generically determine what information, expert opinions,
historical data and treatment costs are needed to proceed with an economic
evaluation. This guide could be utilized when any new candidate substance is
to be evaluated. If more than one evaluation technique is utilized, this
guide, through its logical progression of steps, would indicate the inputs
needed for the particular technique that would be utilized.
2.1.3. The final task of Phase I will be to prepare a detailed work plan
for Phase II. The work plan will describe the data gathering, analysis and
evaluation to be performed in Phase II.
2.2 Phase II--Data Collection and Benefit Evaluation
The thrust of Phase II will be to actually gather data needed to conduct
and to perform the benefit evaluation once the necessary data have been col-
lected. The evaluation techniques chosen in Phase I will be utilized in Phase
II to produce an economic measure of the potential benefits possible from
pursuing space processing of each candidate pharmaceutical substance. It is
anticipated that the results of the Phase II benefit evaluation could be used
for a preliminary ranking of the candidate projects according to the size of
the anticipated benefits. The evaluation of benefits in Phast II will be per-
formed with the assumption that each project has a probability of success of
1.0. The estimated probability of success and failure will be considered in
a decision tree analysis to be perfomed in Phase III. Phase II tasks are
detailed below.
2.2.1. ECON will collect the data necessary to perform the benefit
evaluation analysis.
2.2.2. Once the necessary data are collected, ECON will utilize the
benefit evaluation techniques chosen in Phase I to produce numerical results.
In ECON's previous work, the results were expressed under two forms of bene-
fits: economic and social. The economic benefits will be expressed in terms
of the magnitude of savings available over present health care costs, the
improved earnings possible through improved health or the savings possible
through a decrease in the cost of medication or vaccines. The social benefits
relative to improved physical well-being might include potential years of
extended life, number of years of improved health, reduced number of deaths
or aversion of potential epidemics.
2.2.3. The final task of Phase II will be to prepare the detailed work
plan for Phase III and to specify the computer program needed to perform the
analysis of Phase III.
2.3 Phase III--Program Analysis and Evaluation
It is widely recognized that the possibility of complete success of both
the space processing and subsequent earth-based utilization of the candidate
substance for medical treatment may be low in many cases. This low chance of
success should be evaluated in relation to the often large potential economic
benefit, `hat could accrue from a successful outcome. To do this one must
explicitly take into account the effect of uncertainty and risk.
In Phase III, ECON will arrange candidate substances or processes in a
decision tree fashion, along with other factors of a bioprocessing program.
Costs will then be assessed for each branch of the tree and probabilities of
success and failure will be determined for each branch,. The program options
will then be evaluated to determine their probability of success. The values
for the total benefits possible for each of the candidate substances, obtained
in Phase II, will be utilized at uhis point to perform a rigorous economic
comparison of alternative program plans.
It is anticipated that by the start of Phase III, NASA will have devel-
oped the methodclogy for cost apportionment for Spacelab missions and a cost-
benefit analysis can be performed as a part of this phase.
3.0 Milestone Schedule
Figure 3.1 is the Milestone schedule for this Work Order.
4.0 Manpower Planning
Figure 4.1 shows the manpower planning for this Work Order.
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